HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity.

Abstract
The anti-estrogen, tamoxifen is the most commonly used treatment for patients with estrogen receptor (ER)-alpha-positive breast cancer. Recent data suggest that levels of ER coregulatory proteins as well as extra- and intracellular signaling in response to growth factor stimulation of breast cancer cells play an important role in acquiring resistance to anti-estrogen action. P21-activated kinase 1 (PAK1), a major target of the small GTPases, growth factors and lipid signaling, regulates cell motility, hormone action, invasiveness, and survival, all of which are required for both tumor development and normal mammary gland development. Over the years, the PAK1 has been regarded as cytosolic serine-threonine kinase with regulatory function in cytoskeleton reorganization and motility. However, emerging data now provide evidence of PAK1 function in the nucleus of breast cancer cells. Elevated PAK1 expression in premenopausal breast cancer patients correlates well with the lack of tamoxifen response despite the presence of ER-alpha expression, and such relationship was even distinctly stronger in breast tumors with nuclear PAK1. These typical effects of PAK1 are mechanistically linked with the ability of PAK1 to phosphorylate ER-alpha on serine 305, accompanied by secondary activation of serine 118, and such structural modifications may participate in the development of tamoxifen resistance. These findings suggest that the levels, subcellular localization, and activation status of PAK1 are likely to be important determinants of tamoxifen resistance, and that raising the possibility that tamoxifen resistance might be prevented or reversed by PAK1 inhibition.
AuthorsSuresh K Rayala, Rakesh Kumar
JournalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 61 Issue 7 Pg. 408-11 (Aug 2007) ISSN: 0753-3322 [Print] France
PMID17604944 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Estrogen Receptor alpha
  • Tamoxifen
  • Serine
  • PAK1 protein, human
  • Protein Serine-Threonine Kinases
  • p21-Activated Kinases
Topics
  • Antineoplastic Agents, Hormonal (pharmacology)
  • Breast Neoplasms (drug therapy, enzymology)
  • Cell Nucleus (metabolism)
  • Drug Resistance, Neoplasm
  • Estrogen Receptor alpha (metabolism)
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Phosphorylation
  • Protein Serine-Threonine Kinases (metabolism)
  • Serine (metabolism)
  • Tamoxifen (pharmacology)
  • p21-Activated Kinases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: